Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksE-therapeutics Share News (ETX)

Share Price Information for E-therapeutics (ETX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.75
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.50 (5.263%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 9.75
ETX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK WINNERS & LOSERS SUMMARY: HSBC Shares Fall Amid Investec Downgrade

Wed, 08th Jul 2020 10:45

(Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.

----------

FTSE 100 - LOSERS

----------

HSBC, down 4.1%. Investec downgraded the bank to Hold from Buy.

----------

WPP, down 3.6%. Credit Suisse reinitiated coverage of the advertising giant with Underperform.

----------

FTSE 250 - WINNERS

----------

Pantheon International, up 1.2%. The private equity investor said it expects a slight rise in annual net asset value, outperforming one benchmark but falling short of another. The investor said its net asset value at the May 31 year-end was 2,882.8 pence, up 4.0% year-on-year from 2,770.6p. The 4.0% gain compares favourably to the FTSE All-Share Index which returned negative 11% during the period. Pantheon lagged behind the MSCI World Index which returned 7.4%, however.

----------

FTSE 250 - LOSERS

----------

FirstGroup, down 15%. The Aberdeen-headquartered public transport company posted a GBP299.6 million pretax loss for the year ended March 31, widened from a GBP97.9 million loss the year before. This was due to operating costs, which rose 11% to GBP7.91 billion from GBP7.12 billion and more than offset FirstGroup's revenue rise of 8.7% to GBP7.75 billion from GBP7.13 billion. This resulted in a swing to a GBP152.7 million operating loss from a GBP9.8 million profit. FirstGroup said this swing "reflects charges relating to the North American self-insurance provision, Greyhound impairment charges, restructuring and reorganisation costs and coronavirus-related charges". Finance costs also increased to GBP149.6 million from GBP110.4 million. In March, average passenger volumes fell by around 90% by month end amid lockdowns and school closures in North America.

----------

Victrex, down 5.2%. The polymers manufacturer said sales volume for its third quarter to June 30 was 805 tonnes, down 12% from 912 tonnes in the comparative period the year prior. Revenue was down 18% year-on-year to GBP58.8 million. The decline was attributed to the negative impact of the Covid-19 crisis. Sales volume from the start of the year to June 30 was broadly in line with the previous year. Revenue fell to GBP210.3 million from GBP217.8 million, reflecting a 3% decline. Victrex said the Aerospace, Automotive & Energy markets experienced the greatest level of decline. The deferral of elective procedures in Medical started to hurt performance from April as monthly revenue declines of 40% was recorded however, it added market indicators suggest that procedure deferral will gradually reverse. Looking ahead, the Lancashire-based company said with lower production levels reflecting weaker demand and inventory reduction, and consequently the under-absorption of fixed costs as well as a weaker mix, it expects its margin to be further hurt in the second half and into financial 2020.

----------

OTHER MAIN MARKET AND AIM - WINNERS

----------

Distil, up 17%. The owner of premium drinks brands RedLeg Spiced Rum, Blackwoods Gin and Vodka said unaudited year-on-year first quarter revenue grew by 21%, thanks to an increase in domestic retail sales both in store and on-line across our product range. Volumes were flat in the three months to the end of June year-on-year. Looking forward, Distil said its expectations for the six-month period to September versus the same period prior year are for revenue to increase by between 75% and 85%, which will allow increased marketing investment. Operating profit is expected in the range of GBP50,000 to GBP70,000. In the six months to the end of September 2019, the company reported operating profit of GBP1,000 on turnover of GBP824,000 and marketing costs of GBP219,000.

----------

Hurricane Energy, up 7.2%. The exploration & production company said the 205/21a-6 well on the Lancaster field, offshore UK, has produced at an average rate of 12,000 barrels of oil per day during the second quarter of 2020. The increase in oil production from the 205/21a-6 well implemented on June 5 has, as expected, been accompanied by an increase in produced water. The combined oil production from the 205/21a-6 and 205/21a-7z wells, however, was 1.3 million barrels in the second quarter of 2020, down slightly from 1.4 million barrels reported in the fist quarter. Following the relaxation of Covid-19 restraints on UK offshore operations, on Friday last week the company said it began commissioning the electric submersible pumps in the Lancaster production wells.

----------

OTHER MAIN MARKET AND AIM - LOSERS

----------

E-Therapeutics, down 24% at 13.13 pence. The Oxford, England-based drug discovery company reported a closure of retail offer, raiding GBP750,000. The company said it issued 6.3 million shares at a price of 12p each. The shares were placed at a 31% discount to the closing mid-price on Monday, the latest practicable date prior to the time and date of retail offer announcement. The retail offer is a part of E-Therapeutics' plans to raise up to GBP12.4 million through placing, subscription, retail offer and broker option. The company said it will use the funds raised to facilitate a number of initiatives to enable its next stage of growth and value creation by expanding its platform capabilities and asset pipeline.

----------

boohoo, down 22%. It is launching an immediate independent review of its UK supply chain, led by lawyer Alison Levitt. The fashion retailer said it is also accelerating its independent third party supply chain review with ethical audit and compliance specialists Verisio and Bureau Veritas. In addition, boohoo said it will be making an initial commitment to invest an incremental GBP10 million to eradicate supply chain malpractice. The move comes after Next and ASOS dropped boohoo clothing from their websites after claims that the fast-fashion retailer sold clothes made in factories where staff were paid less than the minimum wage and worked in poor conditions. boohoo has had more than GBP1 billion wiped from its share value in the past two days after an article in the Sunday Times newspaper alleged that workers in a Leicester factory making clothes destined for boohoo were being paid as little as GBP3.50 an hour.

----------

By Evelina Grecenko; evelinagrecenko@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
16 Oct 2013 11:57

UK WINNERS & LOSERS: Hargreaves Continues To Rise, e-Therapeutics Trips

Read more
16 Oct 2013 08:56

e-Therapeutics Pretax Loss Widens As R&D Expenditure Rises

Read more
30 Sep 2013 18:45

DIRECTOR DEALINGS: E-Therapeutics Exec, Wife Combined Shares Total 1.8M

Read more
24 Jul 2013 15:53

Wife of DS Smith CEO sells 5.6m-pound stake

The wife of DS Smith frontman Miles Roberts sold a substantial sum of shares in the packaging and office supplies firm on the same day it was revealed the Chief Executive Officer (CEO) received a big pay increase last year. The move came on Tuesday, the same day DS Smith released its annual report

Read more
14 May 2013 09:46

e-Therapeutics pleases with pipeline progress

News from biotech company e-Therapeutics about the progress of two clinical trials for its cancer drug pleased the markets on Tuesday. The AIM-listed company provided first findings for the company's ETS2101 drug candidate in Phase I trials in the US for patients with brain cancer and in the UK fo

Read more
14 May 2013 08:04

Tuesday broker round-up UPDATE

Babcock International: Jefferies increases target price from 1080p to 1250p and maintains a buy recommendation. Barratt Developments: Bank of America takes target price from 265p to 325p, while downgrading to neutral. Belgravium Technologies: WH Ireland places both its target price and its neutral

Read more
10 May 2013 07:14

Friday broker round-up UPDATE

Afren: Westhouse Securities initiates with a target price of 160p and a buy recommendation. Ashmore Group: Credit Suisse raises target price from 375p to 440p upgrading from underperform to neutral. Barratt Developments: Citigroup increases target price from 245p to 315p leaving its neutral rating

Read more
19 Feb 2013 16:21

Debenhams Executive Director adds to stake

Michael Sharp, the Executive Director of retail chain Debenhams, has topped up his stake in the group with the purchase of 50,000 shares. Sharp, who has been in his current role since September 2011, bought the shares at 97.20p for a total of £48,598. He now holds 6.2m shares in the company. Debe

Read more
11 Feb 2013 09:15

e-Therapeutics shares jump following 40m equity issue

Drug discovery and development company e-Therapeutics is proposing to raise 40m pounds through an issue of new ordinary shares to existing and new institutional investors. The new shares will be priced at 32p, a premium of 4.0% to the closing mid-market price on Friday. Following the proposed issu

Read more
23 Oct 2012 09:23

Tuesday broker round-up

Aggreko: UBS cuts target from 2,750p to 2,550p, buy rating kept. ARM Holdings: Investec keeps buy rating and 800p target. Avacta: Panmure Gordon keeps buy rating and 1.75p target. AZ Electronic: Canaccord Genuity ups target from 360p to 376p, buy rating kept. Babcock: JPMorgan Cazenove ups targe

Read more
22 Oct 2012 08:19

Monday broker round-up - UPDATE

888 Holdings: Morgan Stanley ups target from 125p to 130p, overweight rating kept. Aggreko: Jefferies cuts target from 2,800p to 2,535p, buy rating kept; HSBC downgrades to underweight, target cut from 2,350p to 1,750p; JPMorgan Cazenove cuts target from 2,360p to 2,165p, neutral rating kept; Barcl

Read more
22 Oct 2012 07:53

e-therapeutics produces mixed interims

e-therapeutics, a drug discovery and development company, produced mixed interims with slightly increased losses, but reported progress on its lead cancer drug. As expected, first half losses increased to £1.8m (2011: loss of £1.5m), reflecting increased investment in the business. The company ha

Read more
15 Mar 2011 17:05

Bramson vehicle buys more shares in F&C

F&C Asset Management chairman Edward Bramson's investment vehicle SIGA LP has acquired more shares in the asset management company. Bramson was appointed chairman of F&C last month after a shareholder coup removed the previous incumbent, along with another non-executive, and appointed three new di

Read more
14 Mar 2011 17:19

Wife of outgoing FD sells British Land shares

Diane Roberts, the wife of British Land finance director Graham Roberts, has raised more than £1m by selling more than three-quarters of the couple's stake in the property investor. She sold 191,780 shares at 562.8p each, which raised £1.08m. The couple are left with 50,464 shares in British Land.

Read more
4 Mar 2011 17:03

Shaftesbury boss invests £100,000

Shaftesbury chief executive Jonathan Lane has invested a further £100,000 in the property investor. Lane has bought 22,222 shares at 450p each. That takes his stake to 966,233 shares, which is worth £4.3m at the latest purchase price. Lane raised just over £99,000 from the sale of option shares la

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.